Return-path: <bounce-18416124_HTML-982008319-36128304-10831468-450@bounce.broadcastemail.asco.org>
Envelope-to: info@seeinindia.com
Delivery-date: Sun, 31 May 2015 14:17:22 +0000
Received: from mta.broadcastemail.asco.org ([64.132.92.206]:45360)
	by bh-in-11.webhostbox.net with esmtp (Exim 4.85)
	(envelope-from <bounce-18416124_HTML-982008319-36128304-10831468-450@bounce.broadcastemail.asco.org>)
	id 1Yz43F-003E4q-2k
	for info@seeinindia.com; Sun, 31 May 2015 14:17:22 +0000
Received: by mta.broadcastemail.asco.org id hdcbv2163hsf for <info@seeinindia.com>; Sun, 31 May 2015 08:17:17 -0600 (envelope-from <bounce-18416124_HTML-982008319-36128304-10831468-450@bounce.broadcastemail.asco.org>)
From: "Daily News" <dailynews@asco.org>
To: <info@seeinindia.com>
Subject: Practice-Changing Results from CheckMate 057, Findings from the ONTRAC Study, and More
Date: Sun, 31 May 2015 08:17:12 -0600
List-Unsubscribe: <mailto:leave-fc5015787165027c77101f2d205921-fe271d7877640475761579-fe64177674660c7e7510-fe6015707d670579731c-ff66107575@leave.broadcastemail.asco.org>
MIME-Version: 1.0
x-job: 10831468_36128304
Message-ID: <7e29b80a-773e-4f40-8c3f-e7121a8bfd5a@xtinmta4100.xt.local>
Content-Type: multipart/alternative;
	boundary="klV1vuICvzwk=_?:"
X-Authenticated_sender: 

This is a multi-part message in MIME format.

--klV1vuICvzwk=_?:
Content-Type: text/plain;
	charset="us-ascii"
Content-Transfer-Encoding: 7bit

To view this email as a web page, go to the link below, or copy and paste it into your browser's address window.
http://click.broadcastemail.asco.org/?qs=5806df98e968fae5f7b3848c049f9ee12db47a34712fed1932999319e80ee8c510eed3ad72176b45ASCO
 Advertisement

 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae595dc9cf4ee30ebab2339c9cd4f8178f2fa9081175e542f27ecb161ccc46f82c0 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae5975d9f6a652dd7c9e327d29965b39f03f93c1d32bda91daca73d98e918259eb4 
 
http://click.broadcastemail.asco.org/?qs=5806df98e968fae5975d9f6a652dd7c9e327d29965b39f03f93c1d32bda91daca73d98e918259eb4 
Nivolumab Considered Practice Changing in Refractory, Advanced Nonsquamous NSCLC 

Dr. Luis Paz-Ares (pictured) presented results from the CheckMate 057 trial (Abstract LBA109), which demonstrated a significant overall survival benefit for patients with nonsquamous non&mdash;small cell lung cancer.


http://click.broadcastemail.asco.org/?qs=5806df98e968fae5975d9f6a652dd7c9e327d29965b39f03f93c1d32bda91daca73d98e918259eb4 
Read the Full Story >> 

 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae5bc907ca10e667e605cf129599ee3b189faa1cf84fb97e3f9d5aca7249df6e49a 
Nicotinamide Reduces Nonmelanoma Skin Cancer Formation 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae5bc907ca10e667e605cf129599ee3b189faa1cf84fb97e3f9d5aca7249df6e49a 
 
Dr. Andrew J. Martin (pictured) discussed the results of the ONTRAC study (Abstract 9000), which found that oral nicotinamide significantly reduced the formation of new nonmelanoma skin cancers compared with placebo in patients with severely sun-damaged skin.


http://click.broadcastemail.asco.org/?qs=5806df98e968fae5bc907ca10e667e605cf129599ee3b189faa1cf84fb97e3f9d5aca7249df6e49a 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae59a26f15b541ec3adc47c8934d09d02dfcf8f1a6709a812f3259ca080bff0ed5c 
 
http://click.broadcastemail.asco.org/?qs=5806df98e968fae59a26f15b541ec3adc47c8934d09d02dfcf8f1a6709a812f3259ca080bff0ed5c 
DeCOG Findings Argue Against Complete Lymphadenectomy in Melanoma 

Dr. Daniel G. Coit (pictured) presented the results of a randomized, phase III, noninferiority trial conducted in Germany, which found that performing a complete lymph node dissection after identifying micrometastases in the sentinel lymph nodes does not improve survival outcomes for patients with melanoma (Abstract LBA9002).


http://click.broadcastemail.asco.org/?qs=5806df98e968fae59a26f15b541ec3adc47c8934d09d02dfcf8f1a6709a812f3259ca080bff0ed5c 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae50e76a562391611aa7b6b159a48af5f4757eef916e3a3448fa1227aa0dc966a97 
Nivolumab in HCC and Pembrolizumab in Tumors with Mismatch Repair Deficiency 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae50e76a562391611aa7b6b159a48af5f4757eef916e3a3448fa1227aa0dc966a97 
 
In the Clinical Science Symposium "Immunotherapy for Every Patient: Check Your Enthusiasm," Drs. Anthony B. El-Khoueiry (left) and Dung T. Le reported on the efficacy of nivolumab in hepatocellular carcinoma and pembrolizumab in tumors with mismatch repair deficiency.


http://click.broadcastemail.asco.org/?qs=5806df98e968fae50e76a562391611aa7b6b159a48af5f4757eef916e3a3448fa1227aa0dc966a97 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae5ed7e231c3da31291ef7995183f8e9cf67878e5384f3afc5bdd731fc151cbfe40 
Multidisciplinary Panels: Putting Sequencing Data to Work 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae5ed7e231c3da31291ef7995183f8e9cf67878e5384f3afc5bdd731fc151cbfe40 
 
Dr. Howard L. McLeod (pictured) chaired an ExtendedEducation Session that examined how multidisciplinary tumor boards help with the interpretation of genomic testing results and allow patients and clinicians to sort through the large volume of information produced from genomic testing.


http://click.broadcastemail.asco.org/?qs=5806df98e968fae5ed7e231c3da31291ef7995183f8e9cf67878e5384f3afc5bdd731fc151cbfe40 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae5535bdb125a568888fc4dc810fa1c4257ea076e4dc3f3fd3017a442e3dbf69976 
 
http://click.broadcastemail.asco.org/?qs=5806df98e968fae5535bdb125a568888fc4dc810fa1c4257ea076e4dc3f3fd3017a442e3dbf69976 
ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study 

In this Expert Editorial, Dr. Richard L. Schilsky (pictured) discusses TAPUR, ASCO's first clinical trial, which will focus on facilitating access to approved targeted therapies that are prescribed to patients with advanced cancer for whom standard treatment options have been exhausted.

http://click.broadcastemail.asco.org/?qs=5806df98e968fae5535bdb125a568888fc4dc810fa1c4257ea076e4dc3f3fd3017a442e3dbf69976 
Read the Full Story » 

 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae50bbb54ec485d110a7da8a2338fe3b72b35bdf2bab2925f47c76d9aff8ed71ec7 

http://click.broadcastemail.asco.org/?qs=5806df98e968fae50eb23f26c314957bbf3ef81de81fd448d73292aafb2ae31b8fa38c7a5e299044 

Investing in Cancer Prevention and Control to Reduce Global Economic Burden
 

Dr. Gilberto Lopes (pictured) discusses the global economic burden of cancer, in terms of the direct cost related to the prevention and treatment of the disease and the economic value of lives lost and disability caused, and examines international efforts to reduce it.

http://click.broadcastemail.asco.org/?qs=5806df98e968fae50eb23f26c314957bbf3ef81de81fd448d73292aafb2ae31b8fa38c7a5e299044 
Read the Full Story » 

 
http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bda3cbe7be31e741abdf4a60558eeb3b48a469f1483545204ac36b171e7b2bd084 

http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bd3ab1ad2f892260ddfc53a5ea6dd580ad45987b1442c0af7b2475542fac276d65 

Challenges and Opportunities for Women in Academic Medical Oncology
 

In this Expert Editorial, Drs. S. Gail Eckhardt (left) and Jamie H. Von Roenn discuss work-life balance, the importance of mentors and sponsors, and other issues and opportunities pertaining to women in academic medical oncology.


http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bd3ab1ad2f892260ddfc53a5ea6dd580ad45987b1442c0af7b2475542fac276d65 
Read the Full Story » 

2015 ASCO Special Award Winners

	- 
http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bd74587b4a301cea71385151a32a19b498c1cfd437f16b9d21572ff12160144d54 

Dr. Silvio Monfardini Honored with 2015 B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology
 
	- 
http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bdc00a0151d5c34c5cde6ce03e9e623ca31c3bb3741e22d80951bb17003b268153 
Mary Lou Smith to Receive 2015 Partners in Progress Award  
	- 
http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bd261bb1bd7a0ed7da3f6f9473c48ed64e08ba150771787134d31d56f6f1a83367 

Dr. James P. Allison Honored with Science of Oncology Award
 

 

http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bdb9ee10b0c2d1bbcb8be727df7f1e3e74dcc849c00fbde102c8b07b4a4928a036 
ASCO Daily News Home
http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bd41283bfc4f6d080d4a86cc2ef18b18e94eec152be96f2229b79d966d1ed6de83 
 | 
http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bdce83fae0ddd4e9816f873c21c4cdf5dda10bd139da33c927f4fa20de662aeda4 
Session Coverage  | 
http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bde2c94d7903d5a935c1b80a167d5b2471f4ac3398008f892f644be7a7b649f1e3 
Expert Editorials 

http://click.broadcastemail.asco.org/?qs=f70d1a8582e392bdd831c1f304657694fe7bee7ac7341dff653551a33d03aee373f290a71706b046 
Grants and Awards  | 
http://click.broadcastemail.asco.org/?qs=13a8a60bfbc3f24539e25ebeaf91cc7fcfa3fa1f4bcffd5b11bf32189fd82bebffab4ec62b25d95b 
am.asco.org 

Connect with us:
http://click.broadcastemail.asco.org/?qs=13a8a60bfbc3f2452c6372fa73f0aa56861fef50ba20fb4abac7c71b19ebf8e4257ad6ef3f614fe2 

http://click.broadcastemail.asco.org/?qs=13a8a60bfbc3f24520997a9a09bd9cec132921dd827b67abef4c141053a23aebe1a080ce56da7dc4 

http://click.broadcastemail.asco.org/?qs=13a8a60bfbc3f2457f91423890a60e350ee7766761e57d7339ef18245d64cb577522f971692f3f08 

http://click.broadcastemail.asco.org/?qs=13a8a60bfbc3f2451cf6e4a9bcea6b9bb9c23fdfcdd31bbca93308b518638f748bf909ee0e5f9886 
Forward to a Colleague 
http://click.broadcastemail.asco.org/?qs=13a8a60bfbc3f2451cf6e4a9bcea6b9bb9c23fdfcdd31bbca93308b518638f748bf909ee0e5f9886 

 
http://click.broadcastemail.asco.org/?qs=13a8a60bfbc3f2455607837b58f410ae92bb56ed690dad0335c0373a82d1431dd3f48b1111f8b618 

Advertisement








You are receiving this email because you have an existing relationship
with ASCO.  Visit your personalized 
http://click.broadcastemail.asco.org/?qs=13a8a60bfbc3f245cf68efe1c747e82af94afe7e91950276c216d20dd002c541c69cd846ce17abd7 
Preference Center  to unsubscribe or to select
your preferences for receiving ASCO promotional email.  Please do
not reply to this email.  

This email was sent by: American Society of Clinical Oncology

2318 Mill Road, Suite 800 Alexandria, VA,
22314, USA



--klV1vuICvzwk=_?:
Content-Type: text/html;
	charset="us-ascii"
Content-Transfer-Encoding: 7bit

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<div style="display:block;width:100%;text-align:center;font-family: Verdana, sans-serif;font-size:10px;color:#444444;padding:8px 0;margin:auto;">
	To view this email as a web page, go   <a href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32c391b8fcfc1c12f10019dc0dbd663e57a4fab707f90038d96a6dad0234353216" > here</a>.
</div><!DOCTYPE html>
<html lang="en">

<head>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <title>ASCO</title>

    <style>
        
        body {margin:0; padding:0; -webkit-text-size-adjust:none; -ms-text-size-adjust:none;} img{line-height:100%; outline:none; text-decoration:none; -ms-interpolation-mode: bicubic;} a img{border: none;} #backgroundTable {margin:0; padding:0; width:100% !important; } a, a:link{color:#318786; text-decoration: none;} table td {border-collapse:collapse;} span {color: inherit; border-bottom: none;} span:hover { background-color: transparent; }

    </style>
</head><body style="background: #d8d8d8;font-family:Arial, Helvetica, sans-serif; font-size:1em;">


    <table id="backgroundTable" width="100%" cellspacing="0" cellpadding="0" border="0" style="background:#d8d8d8;">
        <tr>
            <td class="body" align="center" valign="top" style="background:#d8d8d8;" width="100%">
                <table cellpadding="0" cellspacing="0">
                    <tr>
                        <td class="banner" width="826" align="center" style="background: #d8d8d8; padding-top: 16px;">
                            <table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><div align="center"><img vspace="0" hspace="0" border="0" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/GNE_banner_728x90_mm_c2_v3.jpg" title="GNE_banner_728x90_mm_c2_v3" alt="GNE_banner_728x90_mm_c2_v3" /><br /></div><div align="center">&nbsp;</div><div align="center">Advertisement</div></td></tr></table></td></tr></table>&nbsp;
                        </td>
                    </tr>
                    <tr>
                       
                    </tr>
                    <tr>
                        <td class="main" width="826" align="center">
                            <table cellpadding="0" cellspacing="0">
	<tr>
        <td class="header" width="826" align="left">
            
        </td>
    </tr>
    <tr>
    	<td class="subheader" width="826" align="left">
    		<table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><a href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32378794b39254ce6597743a0936bbdcd4ac63572f33f1145723204c742c4e5dc3" title="AM2015 Daily News"  ><img width="826" height="115" border="0" alt="AM15daily-banner-826x115-eDigest" title="AM15daily-banner-826x115-eDigest" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/AM15daily-banner-826x115-eDigest.png" style="width: 826px; height: 115px; border-color: #000000; margin: 0px;" /></a></td></tr></table></td></tr></table>
    	</td>
    </tr>
    <tr>
    	<td width="826" style="background: #d8d8d8;">
    		<table cellpadding="0" cellspacing="0">
    			<tr>
    				<td style="padding: 16px;">
    					<table cellpadding="0" cellspacing="0">
    						<tr>
    							<td width="618" valign="top">
    								<table cellpadding="0" cellspacing="0">
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="168" valign="top">
									<a   title="Nivolumab Considered Practice Changing in Refractory, Advanced Nonsquamous NSCLC" href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32178bb1584199651c84b4ed2ecac1c388ad28b90f46cfe9cafd7fa3de0c807999"><img width="168" height="174" thid="e25d4140-f1dc-4483-9b63-1fe44ca065e2" title="Sun.A.LBA109_Paz-Ares" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Sun.A.LBA109_Paz-Ares.jpg" alt="Sun.A.LBA109_Paz-Ares" style="display: block; border: 0px none; width: 168px; height: 174px; margin: 0px;" /></a>
									</td>
									<td width="24" style="font-size: 1px;">&nbsp;</td>
									<td width="378" valign="top" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
												<a   title="Nivolumab Considered Practice Changing in Refractory, Advanced Nonsquamous NSCLC" href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32178bb1584199651c84b4ed2ecac1c388ad28b90f46cfe9cafd7fa3de0c807999" style="text-decoration: none; color: #318786;">Nivolumab Considered Practice Changing in Refractory, Advanced Nonsquamous NSCLC</a>
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
												Dr. Luis Paz-Ares (pictured) presented results from the CheckMate 057 trial (Abstract LBA109), which demonstrated a significant overall survival benefit for patients with nonsquamous non&mdash;small cell lung cancer.
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
												<a   title=" Nivolumab Considered Practice Changing in Refractory, Advanced Nonsquamous NSCLC" href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32bdb1c16106b02d896331a1e1baece0e8300bca15c8883741f41341cc99752cfb" style="text-decoration: none; color: #318786;">Read the Full Story &raquo;</a>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
									<a href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32ceaf9207086a0e9bcea28daa6a197394ecbb816b13b472740d7081996ff367fa" style="text-decoration: none; color: #318786;" title="Nicotinamide Reduces Nonmelanoma Skin Cancer Formation"  >Nicotinamide Reduces Nonmelanoma Skin Cancer Formation</a>
									</td>
								</tr>
								<tr>
									<td width="570" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td width="284" valign="top">
												<a href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32ceaf9207086a0e9bcea28daa6a197394ecbb816b13b472740d7081996ff367fa" title="Nicotinamide Reduces Nonmelanoma Skin Cancer Formation"  ><img width="284" height="148" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/AM15_Sun-9000_284x148.jpg" alt="AM15_Sun-9000_284x148" style="display: block; border: 0px none; width: 284px; height: 148px; margin: 0px;" title="AM15_Sun-9000_284x148" thid="4b330a47-3c52-4663-836c-0eff5525a106" /></a>
												</td>
												<td width="24" style="font-size: 1px;">&nbsp;</td>
												<td width="262" valign="top" align="left">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
															Dr. Andrew J. Martin (pictured) discussed the results of the ONTRAC study (Abstract 9000), which found that oral nicotinamide significantly reduced the formation of new nonmelanoma skin cancers compared with placebo in patients with severely sun-damaged skin.
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32ceaf9207086a0e9bcea28daa6a197394ecbb816b13b472740d7081996ff367fa" style="text-decoration: none; color: #318786;" title="Nicotinamide Reduces Nonmelanoma Skin Cancer Formation"  >Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="168" valign="top">
									<a   title="DeCOG Findings Argue Against Complete Lymphadenectomy in Melanoma " href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb326178b11aebb8f370893346f724d06523b31693e0a5e6866f728133f3c0d99f1d"><img width="168" height="174" thid="7df3e7e9-3863-4b51-8842-70fe899a64f3" title="AM15_Sun_headshotjpg" style="display: block; border: 0px none; width: 168px; height: 174px; margin: 0px;" alt="AM15_Sun_headshotjpg" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/AM15_Sun_headshotjpg.jpg" /></a>
									</td>
									<td width="24" style="font-size: 1px;">&nbsp;</td>
									<td width="378" valign="top" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
												<a   title="DeCOG Findings Argue Against Complete Lymphadenectomy in Melanoma" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb3266023f18e7f50f3171f95a1a0e3ba395579e5a5404d3c604afeac3a701cb401d">DeCOG Findings Argue Against Complete Lymphadenectomy in Melanoma</a>
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
Dr. Daniel G. Coit (pictured) presented the results of a randomized, phase III, noninferiority trial conducted in Germany, which found that performing a complete lymph node dissection after identifying micrometastases in the sentinel lymph nodes does not improve survival outcomes for patients with melanoma (Abstract LBA9002).
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
												<a   title="DeCOG Findings Argue Against Complete Lymphadenectomy in Melanoma" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb3266023f18e7f50f3171f95a1a0e3ba395579e5a5404d3c604afeac3a701cb401d">Read the Full Story &#187;</a>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
									<a href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32b477a58864bd0934635de13ff858bdee5cca63c723bc65299443566190994ea9" style="text-decoration: none; color: #318786;" title="Nivolumab in HCC and Pembrolizumab in Tumors with Mismatch Repair Deficiency"  >Nivolumab in HCC and Pembrolizumab in Tumors with Mismatch Repair Deficiency</a>
									</td>
								</tr>
								<tr>
									<td width="570" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td width="284" valign="top">
												<a href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32b477a58864bd0934635de13ff858bdee5cca63c723bc65299443566190994ea9" title="Nivolumab in HCC and Pembrolizumab in Tumors with Mismatch Repair Deficiency"  ><img width="284" height="148" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/immuno+combined.png" alt="immuno combined" style="display: block; border: 0px none; width: 284px; height: 148px; margin: 0px;" title="immuno combined" thid="2eeed3cb-c9c7-4b37-9fe6-36275e85f73b" /></a>
												</td>
												<td width="24" style="font-size: 1px;">&nbsp;</td>
												<td width="262" valign="top" align="left">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
In the Clinical Science Symposium "Immunotherapy for Every Patient: Check Your Enthusiasm," Drs. Anthony B. El-Khoueiry (left) and Dung T. Le reported on the efficacy of nivolumab in hepatocellular carcinoma and pembrolizumab in tumors with mismatch repair deficiency.  
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb32ea5705478a6647853dc5e942bc13c9d553c0ceeb56b02c74e9c98a29037d04aa" style="text-decoration: none; color: #318786;" title=" Nivolumab in HCC and Pembrolizumab in Tumors with Mismatch Repair Deficiency"  >Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
									<a href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb322678fa07c275364c55ff4f05963bb6c95dbe249c866f5bc66dcd2444dbe1e057" style="text-decoration: none; color: #318786;" title="Multidisciplinary Panels: Putting Sequencing Data to Work"  >Multidisciplinary Panels: Putting Sequencing Data to Work</a>
									</td>
								</tr>
								<tr>
									<td width="570" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td width="284" valign="top">
												<a   title="Multidisciplinary Panels: Putting Sequencing Data to Work" href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb322678fa07c275364c55ff4f05963bb6c95dbe249c866f5bc66dcd2444dbe1e057"><img width="284" height="148" title="AM15_Sun-Curve_284x148" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Sun.A.Curve_McLeod.jpg" alt="AM15_Sun-Curve_284x148" style="display: block; border: 0px none; width: 284px; height: 148px; margin: 0px;" thid="f32e058b-b993-431f-89c1-a52997583a95" /></a>
												</td>
												<td width="24" style="font-size: 1px;">&nbsp;</td>
												<td width="262" valign="top" align="left">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
Dr. Howard L. McLeod (pictured) chaired an Extended  Education Session that examined how multidisciplinary tumor boards help with the interpretation of genomic testing results and allow patients and clinicians to sort through the large volume of information produced from genomic testing.
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a href="http://click.broadcastemail.asco.org/?qs=5a385a3343f7eb322678fa07c275364c55ff4f05963bb6c95dbe249c866f5bc66dcd2444dbe1e057" style="text-decoration: none; color: #318786;" title="Multidisciplinary Panels: Putting Sequencing Data to Work"  >Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="168" valign="top">
									<a   title=" ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb4985365dc7a3d358bef7b8b30c09aa3fdaa5b8b3e48efda0d42aa9083b25747fc1e83"><img width="168" height="174" thid="aebd5507-5796-4457-932e-470752f3802a" title="AMDN15.EE.Schilsky_crop" style="display: block; border: 0px none; width: 168px; height: 174px; margin: 0px;" alt="AMDN15.EE.Schilsky_crop" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/AMDN15.EE.Schilsky_crop.jpg" /></a>
									</td>
									<td width="24" style="font-size: 1px;">&nbsp;</td>
									<td width="378" valign="top" align="left">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
												<a   title=" ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb4985365dc7a3d358bef7b8b30c09aa3fdaa5b8b3e48efda0d42aa9083b25747fc1e83">ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study</a>
												</td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
In this Expert Editorial, Dr. Richard L. Schilsky (pictured) discusses TAPUR, ASCO's first clinical trial, which will focus on facilitating access to approved targeted therapies that are prescribed to patients with advanced cancer for whom standard treatment options have been exhausted.<br /></td>
											</tr>
											<tr>
												<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
												<a   title=" ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb4985365dc7a3d358bef7b8b30c09aa3fdaa5b8b3e48efda0d42aa9083b25747fc1e83">Read the Full Story &#187;</a>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
    									<tr>
    										<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" style="padding-bottom: 16px;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td width="301" valign="top">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="301" align="center" style="background: #ffffff none repeat scroll 0% 0%;">
									<a   title=" Investing in Cancer Prevention and Control to Reduce Global Economic Burden" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb4985306ae4891c169fb6c442ba79d7d9dbf5116d0df744b800d9fd3fd99c15c07b29a"><img width="250" height="190" thid="14b70eb5-7a6e-421f-913f-b8dbbbd06290" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/Lopes_Gilberto-crop.jpg" alt="Lopes_Gilberto-crop" style="display: block; border: 0px none; width: 250px; height: 190px; margin: 0px;" title="Lopes_Gilberto-crop" /></a>
									</td>
								</tr>
								<tr>
									<td width="301" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td style="padding: 20px 24px;">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
															<a   title=" Investing in Cancer Prevention and Control to Reduce Global Economic Burden" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb49853202cfe1ad81ea6877583e8d8840e88c9c13a8e8ea0c5ccc1d722e906923d556e" style="text-decoration: none; color: #318786;">
															Investing in Cancer Prevention and Control to Reduce Global Economic Burden
															</a>
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
															Dr. Gilberto Lopes (pictured) discusses the global economic burden of cancer, in terms of the direct cost related to the prevention and treatment of the disease and the economic value of lives lost and disability caused, and examines international efforts to reduce it.</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a   title=" Investing in Cancer Prevention and Control to Reduce Global Economic Burden" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb49853202cfe1ad81ea6877583e8d8840e88c9c13a8e8ea0c5ccc1d722e906923d556e" style="text-decoration: none; color: #318786;">Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
						<td width="16" style="font-size: 1px;">&nbsp;</td>
						<td width="301" valign="top">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td width="301" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
									<a   title=" Challenges and Opportunities for Women in Academic Medical Oncology" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb49853be22cae469146b3bfd641d913e4a55aa02adb4ba602562af32e281942d3f868a"><img width="301" height="190" mdid="a6ed944e-2e7a-49ff-a148-0c5f7bdaab4f" title="combined_Eckhardt and Von Roenn" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/combined_Eckhardt+and+Von+Roenn.jpg" alt="combined_Eckhardt and Von Roenn" style="display: block; border: 0px none; width: 301px; height: 190px; margin: 0px;" /></a>
									</td>
								</tr>
								<tr>
									<td width="301" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
									<table cellspacing="0" cellpadding="0">
										<tbody>
											<tr>
												<td style="padding: 20px 24px;">
												<table cellspacing="0" cellpadding="0">
													<tbody>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786; padding-bottom: 12px;">
															<a   title="Challenges and Opportunities for Women in Academic Medical Oncology " href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb49853ad9e7dccda464d6a3974700190c6a8a4de379682acc134a47c6cb03ba4d535e2" style="text-decoration: none; color: #318786;">
															Challenges and Opportunities for Women in Academic Medical Oncology
															</a>
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 14px; color: #747474; padding-bottom: 16px; line-height: 18px ! important;">
															<br />In this Expert Editorial, Drs. S. Gail Eckhardt (left) and Jamie H. Von Roenn discuss work-life balance, the importance of mentors and sponsors, and other issues and opportunities pertaining to women in academic medical oncology.
															<br />
															<br />
															</td>
														</tr>
														<tr>
															<td align="left" style="font-family: arial,sans-serif; font-size: 18px; font-weight: bold; color: #318786;">
															<a   title="Challenges and Opportunities for Women in Academic Medical Oncology " href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb49853ad9e7dccda464d6a3974700190c6a8a4de379682acc134a47c6cb03ba4d535e2" style="text-decoration: none; color: #318786;">Read the Full Story &#187;</a>
															</td>
														</tr>
													</tbody>
												</table>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
    									</tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="left" style="background: #ffffff none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td style="padding: 20px 24px;">
						<table cellspacing="0" cellpadding="0">
							<tbody>
								<tr>
									<td align="left" style="padding-bottom: 12px; font-family: arial,sans-serif; color: #318786; font-size: 18px; font-weight: bold;">2015 ASCO Special Award Winners</td>
								</tr>
								<tr>
									<td align="left" style="padding-bottom: 16px; line-height: 18px ! important; font-family: arial,sans-serif; color: #747474; font-size: 14px;">
									<table width="502" height="147" cellspacing="0" cellpadding="0" style="font-family: arial;">
										<tbody>
											<tr>
												<td align="left" style="padding-bottom: 16px; line-height: 18px ! important; font-family: arial,sans-serif; color: #747474; font-size: 14px;">
												<ul>
													<li><a style="color: #318786; text-decoration: none;" title=" Dr. Silvio Monfardini Honored with 2015 B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb49853487b3ed857f8f149f97d81d964f0533e46892836074dac95f77089f675225709"  >
													Dr. Silvio Monfardini Honored with 2015 B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology
													</a></li>
													<li><a style="color: #318786; text-decoration: none;" title="Mary Lou Smith to Receive 2015 Partners in Progress Award " href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb49853afbba340a10179fde683628e2f93020b2540243424f66c79f0d1877210dfae65"  >Mary Lou Smith to Receive 2015 Partners in Progress Award </a></li>
													<li><a style="color: #318786; text-decoration: none;" title=" Dr. James P. Allison Honored with Science of Oncology Award" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb498533c57b97b2890c6b588baa52acbb69ef718cdf1c4b50e90548c96cdd8244ad66c"  >
Dr. James P. Allison Honored with Science of Oncology Award
</a></li>
													
												</ul>
												</td>
											</tr>
										</tbody>
									</table>
									</td>
								</tr>
							</tbody>
						</table>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
		<tr>
			<td width="618" height="16" style="font-size: 1px;">&nbsp;</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellspacing="0" cellpadding="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="center" style="border-top: 1px solid #ffffff; border-bottom: 2px solid #ffffff; padding: 12px 0px; background: #d2e8e2 none repeat scroll 0% 0%;">
			<table cellspacing="0" cellpadding="0">
				<tbody>
					<tr>
						<td align="center" style="font-family: arial,sans-serif; font-size: 16px; font-weight: bold; color: #6a6a6a; line-height: 30px ! important;">
						<a title="https://am.asco.org/daily-news" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb4985372928733acf082f97a244ae6533eb2f74ac6a3c0f654d7f1311ea9d044f65607"  ><i>ASCO Daily News</i> Home</a><a   title="ASCO Daily News Home" href="http://click.broadcastemail.asco.org/?qs=b0903ab1cfb49853f05280d3543e7666cf3e0dcf4ced82790cfe2b56f2a5657b4b22ec41e5a100c69b98970f140d3d67"></a> | <a   title="Session coverage" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca104cc4ccec8370f1329b106a74ab6aa17c2ef0e4e979dee692289a227614c133f73a5609c824b94853">Session Coverage</a> | <a   title="Expert editorials" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca107e3cf3477f293964275229450702dd81609c028d3ac786b38bdcab9ee12e67dcef1e7a834c27a377">Expert Editorials</a>
						</td>
					</tr>
					<tr>
						<td align="center" style="font-family: arial,sans-serif; font-size: 16px; font-weight: bold; color: #6a6a6a; line-height: 30px ! important;">
						<a   title="Grants and Awards" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca10538208e0a4fbab07405614beaf9a99487c91edce804b0ed57478dbc98cad418da015779f2760f7d7">Grants and Awards</a> | <a   title="am.asco.org" style="text-decoration: none; color: #318786;" href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca10f9156c16cca90b7f254ce890c874930ce92a2a665d511454f127f8214b4f953cbe1d9f8df8059843">am.asco.org</a>
						</td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
									    <tr>
									    	<td width="618"><table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><table cellpadding="0" cellspacing="0" class="dashedBorder">
	<tbody>
		<tr>
			<td width="618" align="center" style="padding: 12px 0px; background: #efefef;">
			<table cellpadding="0" cellspacing="0">
				<tbody>
					<tr>
						<td style="font-family: arial, sans-serif; font-size: 16px; color: #575757; padding-right: 10px;">Connect with us:</td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca100dc088da4088d15b35ebe21313451b4487dffb71bea6a1ba0e7cf7c38afa77f35e65544cd4e77f2d" title="Twitter"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_11.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca10e912f5a6c0ae5492848d7a307d015208978847d94e10d268560bb23ca53429d73f99348259c87e0b" title="Facebook"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_13.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 10px;"><a href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca100c307adfca6514e811be40d8e40e48413d3874ac9a728dd8fbc16c03a9fbf3af52437231a72a3495" title="Linkedin"  ><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_15.jpg" style="display: block; border: 0px; width: 32px; height: 32px; margin: 0px;" width="32" height="32" /></a></td>
						<td style="padding-right: 20px;"></td>
						<td style="font-family: arial, sans-serif; font-size: 16px; color: #575757; padding-right: 10px;">
						<a href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca106e33a8c3791ac992f7c460fc7655a9c971558c0954e4cc7b9e9cd15e05a0c1de" style="text-decoration: none; color: #318786;">Forward to a Colleague</a>
						</td>
						<td><a href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca106e33a8c3791ac992f7c460fc7655a9c971558c0954e4cc7b9e9cd15e05a0c1de"><img src="http://image.broadcastemail.asco.org/lib/fe66157077670d7f7712/m/1/eDigest_19.jpg" alt="Email" style="display: block; border: 0px;" /></a></td>
					</tr>
				</tbody>
			</table>
			</td>
		</tr>
	</tbody>
</table></td></tr></table></td></tr></table></td>
									    </tr>
    								</table>
    							</td>
    							<td width="16" style="font-size: 1px; min-width: 16px;">&nbsp;</td>
    							<td width="160" valign="top">
    								<table cellpadding="0" cellspacing="0" border="0" bordercolor="" width="100%" bgcolor=""><tr><td><table  width="100%" bgcolor="" border="0" bordercolor="" cellpadding="0" cellspacing="0"><tr><td style="font-family:Arial; font-size:13px"><div align="center"><a   title="ASCO Connection" href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca10eecf0ad3d509ee5fa8849cc5ce2d41915745eaaa487e40d6c25318c42d815dd4"><img width="160" height="600" border="0" style="width: 160px; height: 600px; border-color: #000000; margin: 0px;" src="http://image.broadcastemail.asco.org/lib/fe6015707d670579731c/m/1/AC-web-ad-160x600_2015-05-26.png" title="AC-web-ad-160x600_2015-05-26" alt="AC-web-ad-160x600_2015-05-26" /></a><br />Advertisement</div></td></tr></table></td>
</tr></table>
    							</td>
    						</tr>
    					</table>
    				</td>
    			</tr>
    		</table>
    	</td>
    </tr>
    <tr>
    	<td class="disclaimer" width="826" align="center">
    		
    	</td>
    </tr>
</table>
                        </td>
                    </tr>
                    <tr>
                      
                                            </tr>
                                        </table>
                                    </td>
                                </tr>
                            </table>
                        </td>
                    </tr>
                </table>
            </td>
        </tr>
    </table>

    <!-- Exact Target tracking code -->
    <img src="http://click.broadcastemail.asco.org/open.aspx?ffcb10-fe64177674660c7e7510-fdc61574706c037c7112727664-fe6015707d670579731c-fe6415787165027c7710-fe271d7877640475761579-ff66107575" width="1" height="1">

</body>
 <!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<title></title>
</head><body style="background: #d8d8d8;font-family:Arial, Helvetica, sans-serif; font-size:1em;">
<body>


<div width="850" style="margin-left: auto; margin-right: auto; width: 850px; text-align: left;">

You are receiving this email because you have an existing relationship
with ASCO.&nbsp; Visit your personalized <a
href="http://click.broadcastemail.asco.org/?qs=4dda871b01aaca10d5e102608e66ad50c3a8c9e15312f829eb19237b9375dc2b2a20ef62b821b648"
target="_blank">Preference Center</a> to unsubscribe or to select
your preferences for receiving ASCO promotional email.&nbsp; Please do
not reply to this email.&nbsp; <br>
This email was sent by: American Society of Clinical Oncology<br>
2318 Mill Road, Suite 800 Alexandria, VA,
22314, USA<br></div>
</body>
</body>
</html>

--klV1vuICvzwk=_?:--

